The use of antibodies against p53 as serological marker in the clinical management of colorectal cancer patients has been reported, but the prognostic value of such antibodies (Kressner et al, 1998) and their potential use for prediction of curability (Takeda et al, 2001) or response to adjuvant chemotherapy (Lechpammer et al, 2004) are conflicting. Here, TP53 is linked to colorectal cancer.